
    
      1. brief enrollment criteria

             -  histological confirmed

             -  refractory to first line gemcitabine plus cisplatin

             -  fit for chemotherapy

        2. treatment arms A. mFOLFOX D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr
           5FU 2400mg/m2 over 46hr Every 2 weeks

           B. mFOLFIRI D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2
           over 46hr Every 2 weeks

        3. randomization - stratified by tumor site and performance status
    
  